Alnylam sees Amvuttra as potential standard of care in ATTR-CM
Aug 30, 2024 · Alnylam is circling the bases after walloping—in the words of chief medical officer Pushkal Garg M.D.—a “grand slam” with data that position its RNA silencer Amvuttra …
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Amvuttra sales contribute significantly to Alnylam’s top line. The drug generated sales worth $693.9 million in the nine months ended Sept. 30, 2024, up 79% on a reported basis.
Alnylam Seeks Accelerated FDA Approval of Amvuttra for Rare …
Oct 9, 2024 · The FDA in 2022 approved Amvuttra to treat adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, a rare debilitating disease that damages …
Alnylam grabs FDA approval for its second amyloidosis therapy
4 days ago · Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which …
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra …
1 day ago · Just three days after approving BridgeBio’s Attruby for transthyretin amyloid cardiomyopathy, the FDA has accepted Alnylam’s application to expand Amvuttra’s label to …
Jun 24, 2024 Press Release for Alnylam - Alnylam Pharmaceuticals, …
Jun 24, 2024 · Reduced Serum Vitamin A Levels and Recommended Supplementation. AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels. …
Alnylam’s (ALNY) Amvuttra Meets Goal in Closely Watched Heart …
Jun 24, 2024 · A study released Monday found that Alnylam’s vutrisiran, which is sold as Amvuttra, helped patients with a serious heart condition known as known as ATTR …
Alnylam Announces FDA Approval of AMVUTTRA ... - Business Wire
Jun 13, 2022 · AMVUTTRA™ (vutrisiran) is an RNAi therapeutic approved in the United States for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis …
Alnylam Submits Supplemental New Drug Application (sNDA) to …
Oct 9, 2024 · Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults. As …
Oct 09, 2024 Press Release for Alnylam
Oct 9, 2024 · AMVUTTRA® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of mutant and wild-type transthyretin (TTR), addressing the underlying cause of transthyretin …